Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 56

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 56
---
 Keystone Purchase Agreement.

During the three months ended
March 31, 2025, the Company sold 14,531 shares of common stock of the Company for net proceeds of $1,227,241 under the November 2024 Keystone
Purchase Agreement. Additionally, in January 2025, the Company received net proceeds of $716,694 from the collection of stock subscription
receivable, which was reflected as a stock subscription receivable on December 31, 2024. The Company sought and received a waiver to sell
the shares below the applicable minimum price in the agreement.

During the three months
ended June 30, 2025, the Company sold 75,064 shares of common stock of the Company for net proceeds of $481,971 under the November 2024
Keystone Purchase Agreement.

During the three months ended
September 30, 2025, the Company sold 253,682 shares of common stock of the Company for net proceeds of $1,278,217 under the July 2025
Keystone Purchase Agreement.

Issuance of Common Stock to Arena Business Solutions Global SPC II, Ltd. (“Arena”) for the Arena ELOC

On February 23, 2024, the
Company entered into a common stock purchase agreement (the “Arena Purchase Agreement”) with Arena, pursuant to which we may
sell and issue, and Arena is obligated to purchase, up to $25,000,000 of Common Stock. The price of the shares purchased by Arena under
the ELOC is 90% of various VWAP and closing price-based formulae, and requires a waiver, should the selling price be below $500.00 per
share. As consideration for Arena commitment to purchase shares of Common Stock pursuant to the Arena Purchase Agreement, in May 2024,
the Company issued 173 shares of Common Stock to Arena valued at $500,000, which is reflected as deferred offering costs on the accompanying
consolidated balance sheet as of December 31, 2024. The Company has sold no shares of Common Stock to Arena under the Arena ELOC during
the nine months ended September 30, 2025 and 2024. As of September 30, 2025, the Company wrote off the deferred offering costs of $500,000
since the likelihood of raising funds pursuant to the Arena Purchase Agreement is unlikely. Accordingly, during the three and nine months
ended September 30, 2025, the Company recorded a